The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Open accessAbstract
BACKGROUND: Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy. METHODS: In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight. In part 2, the dose-expansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice monthly (8 doses), and monthly for up to 24 months. End points included safety, efficacy, and pharmacokinetics. RESULTS: No maximum tolerated dose was identified in part 1. In part 2, the median time since diagnosis was 5.7 years. Patients had received a median of four prior treatments; 79% of the patients had disease that was refractory to the last therapy received (64% had disease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to bortezomib and lenalidomide), and 76% had received autologous stem-cell transplants. Infusion-related reactions in part 2 were mild (71% of patients had an event of any grade, and 1% had an event of grade 3), with no dose-dependent adverse events. The most common adverse events of grade 3 or 4 (in ≥ 5% of patients) were pneumonia and thrombocytopenia. The overall response rate was 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete response and 2 with a very good partial response) and 10% in the cohort that received 8 mg per kilogram (3 had a partial response). In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had a response did not have progression at 12 months. CONCLUSIONS: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab is active in relapsed, refractory multiple myeloma.85”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citationSiegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 664
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma
Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4tb90buwh27jx · Cited by 454
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Self-citationZonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Afifi, S., Michael, A., & Lesokhin, A. M. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016642786 · Cited by 26
Novel targets for the treatment of relapsing multiple myeloma
Giuliani, N., Accardi, F., Marchica, V., Palma, B. D., Storti, P., Toscani, D., Vicario, E., & Malavasi, F. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1624158 · Cited by 28
Marsh‐Wakefield, F., Kruzins, A., McGuire, H. M., Yang, S., Bryant, C. E., Groth, B. F. D. S., Nassif, N. T., Byrne, S. N., Gibson, J., Brown, C. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01596 · Cited by 24
Will Daratumumab be the next game changer in early thymic precursor‐acute lymphoblastic leukaemia?
Mirgh, S. P., Ahmed, R., Agrawal, N., Khushoo, V. K., Garg, A., Thekuddan, S. F., Tejwani, N., Singh, N., & Bhurani, D. (2019) · British Journal of Haematology · doi:10.1111/bjh.16154 · Cited by 26
Schriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., et al. (2020) · Theranostics · doi:10.7150/thno.38533 · Cited by 27
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 27
Self-citationKirchhoff, D., Murata, K., & Thoren, K. L. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab055 · Cited by 26
The real-world outcomes of multiple myeloma patients treated with daratumumab
Szabo, A. G., Klausen, T. W., Levring, M. B., Preiss, B., Helleberg, C., Breinholt, M. F., Hermansen, E., Gjerdrum, L. M. R., Bønløkke, S. T., Nielsen, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258487 · Cited by 26
Atrash, S., Thompson‐Leduc, P., Tai, M., Kaila, S., Gray, K. S., Ghelerter, I., Lafeuille, M., Lefèbvre, P., & Rossi, A. (2021) · BMC Cancer · doi:10.1186/s12885-021-08881-7 · Cited by 26
An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy
Quazi, S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.12.003 · Cited by 24
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis
Minnema, M. C., Dispenzieri, A. A., Merlini, G., Comenzo, R. L., Kastritis, E., Wechalekar, A. D., Grogan, M. A., Witteles, R. M., Ruberg, F. L., Maurer, M. S., et al. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.08.011 · Cited by 26
Self-citationTumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
Laubach, K., Turan, T., Mathew, R. S., Wilsbacher, J. L., Engelhardt, J., & Samayoa, J. A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.60 · Cited by 27
Gaballa, S. R., Saliba, R. M., Srour, S. A., Lu, G. G., Brammer, J. E., Shah, N. D., Bashir, Q., Patel, K. K., Bock, F. M., Parmar, S., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24487 · Cited by 27
The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma
Rotolo, A., Caputo, V. S., & Karadimitris, A. (2016) · British Journal of Haematology · doi:10.1111/bjh.13976 · Cited by 25
Salomon‐Perzyński, A., Walter‐Croneck, A., Usnarska‐Zubkiewicz, L., Dytfeld, D., Zielińska, P., Wojciechowska, M., Hołojda, J., Robak, P. J., Pasternak, A., Knopińska‐Posłuszny, W., et al. (2019) · Advances in Medical Sciences · doi:10.1016/j.advms.2019.05.001 · Cited by 25
Storti, P., Vescovini, R., Costa, F., Marchica, V., Toscani, D., Palma, B. D., Craviotto, L., Malavasi, F., & Giuliani, N. (2020) · British Journal of Haematology · doi:10.1111/bjh.16548 · Cited by 25
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
D’Agostino, M., Innorcia, S., Boccadoro, M., & Bringhen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218192 · Cited by 28
Daratumumab in rituximab‐refractory autoimmune haemolytic anaemia
Rieger, M. J., Stolz, S. M., Ludwig, S., Benoit, T. M., Bissig, M., Widmer, C. C., Schwotzer, R., Müller, A. M. S., Nair, G., Hegemann, I., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17655 · Cited by 25
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
Morè, S., Offidani, M., Corvatta, L., Petrucci, M. T., & Fazio, F. (2023) · Cancers · doi:10.3390/cancers15112948 · Cited by 26
Oostvogels, R., Jak, M., Raymakers, R. A. P., Mous, R., & Minnema, M. C. (2018) · British Journal of Haematology · doi:10.1111/bjh.15504 · Cited by 25
Self-citationHirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01909-7 · Cited by 25
Waldschmidt, J. M., Anand, P., Knoechel, B., & Lohr, J. G. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.02.010 · Cited by 25
van de Donk, N. W. C. J., Casneuf, T., Cara, A. D., Parren, P. W. H. I., Zweegman, S., van Kessel, B., Lokhorst, H. M., Usmani, S. Z., Lonial, S., Richardson, P. G. G., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15122 · Cited by 24
Self-citationDemel, I., Bago, J., Hájek, R., & Jelı́nek, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.17235 · Cited by 25
Rosenberg, A. S., Brunson, A. M., Tuscano, J. M., Jonas, B. A., Hoeg, R. T., Wun, T., & Keegan, T. H. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00400-4 · Cited by 24
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
Kassem, S., Diallo, B., El-Murr, N., Carrié, N., Tang, A., Fournier, A., Bonnevaux, H., Nicolazzi, C., Cuisinier, M., Reguigne-Arnould, I., et al. (2022) · Blood · doi:10.1182/blood.2021012448 · Cited by 24
Voorhees, P. M., Suman, V. J., Tuchman, S. A., Laubach, J. P., Hassoun, H., Efebera, Y. A., Mulkey, F. A., Bova‐Solem, M., Santo, K., Carlisle, D., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26361 · Cited by 24
Self-citationDaratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
Terpos, E., Ntanasis‐Stathopoulos, I., Kastritis, E., Hatjiharissi, E., Katodritou, E., Eleutherakis‐Papaiakovou, E., Verrou, E., Gavriatopoulou, M., Leonidakis, A., Manousou, K., et al. (2022) · Cancers · doi:10.3390/cancers14112768 · Cited by 26
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 25
CD 38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy
Minařík, J., Novák, M., Flódr, P., Balcárková, J., Mlynárčiková, M., Krhovská, P., Pika, T., Pikalová, Z., Bačovský, J., & Ščudla, V. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12902 · Cited by 24
Multiple Sclerosis: B Cells Take Center Stage
Pröbstel, A., & Hauser, S. L. (2018) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000642 · Cited by 25
Carreño‐Tarragona, G., Cedena, M., Montejano, L., Alonso, R., Mirás, F., Valeri, A., Rivero, A., Lahuerta, J. J., & Martínez‐López, J. (2018) · Transfusion Medicine · doi:10.1111/tme.12508 · Cited by 24
Walker, Z. J., VanWyngarden, M. J., Stevens, B. M., Abbott, D., Hammes, A., Langouët-Astrié, C. J., Smith, C. A., Palmer, B. E., Forsberg, P. A., Mark, T. M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000122 · Cited by 24
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 25
Miguel, J. F. S., Einsele, H., & Moreau, P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0413-7 · Cited by 25
Targeting GPRC5D for multiple myeloma therapy
Zhou, D., Wang, Y., Chen, C., Li, Z., Xu, K., & Zhao, K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01611-z · Cited by 23
Multiple Myeloma: What Do We Do About Immunodeficiency?
Li, L., & Wang, L. (2019) · Journal of Cancer · doi:10.7150/jca.29993 · Cited by 23
Huang, H., Wu, H., & Hu, Y. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900351 · Cited by 22
Afram, G., Gran, C., Bruchfeld, J. B., Wagner, A. K., Hussain, A., Alici, E., & Nahi, H. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13426 · Cited by 23
Self-citationRapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 23
Robbrecht, D. G. J., Jungels, C., Mau‐Sørensen, M., Spanggaard, I., Eskens, F. A. L. M., Fretland, S. Ø., Guren, T. K., Aftimos, P. G., Liberg, D., Svedman, C., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01657-7 · Cited by 23
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies
Kale, A., Lech, M., Anders, H., & Gaikwad, A. B. (2023) · BioDrugs · doi:10.1007/s40259-023-00597-3 · Cited by 24
CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
Li, H., Song, W., Wu, J., Shi, Z., Gao, Y., Li, J. Y., Han, L., Zhang, J., Li, Z., Li, Y., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03040-0 · Cited by 23
Rosenberg, A. S., Pariser, A., Diamond, B., Yao, L. P., Turka, L. A., Lacaná, E., & Kishnani, P. S. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.02.009 · Cited by 23
Development of Novel Immunotherapies for Multiple Myeloma
Al-Hujaily, E. M., Oldham, R. A. A., Hari, P., & Medin, J. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091506 · Cited by 25
Venkatakrishnan, K., & Ecsedy, J. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.544 · Cited by 23
Boyle, E. M., Leleu, X. P., Petillon, M., Karlin, L., Doyen, C., Demarquette, H., Royer, B., Macro, M., Moreau, P., Fostier, K., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16059 · Cited by 23
CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
Frerichs, K. A., Verkleij, C. P. M., Bosman, P. W. C., Zweegman, S., Otten, H. G., & van de Donk, N. W. C. J. (2019) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2019.100022 · Cited by 23
Plesner, T., van de Donk, N. W. C. J., & Richardson, P. G. G. (2020) · Cells · doi:10.3390/cells9020378 · Cited by 23
Self-citationHosny, M., Verkleij, C. P. M., van der Schans, J., Frerichs, K. A., Mutis, T., Zweegman, S., & van de Donk, N. W. C. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194593 · Cited by 24
Blanquart, E., Ekren, R., Rigaud, B., Joubert, M.-V., Baylot, V., Daunes, H., Cuisinier, M., Villard, M., Carrié, N., Mazzotti, C., et al. (2024) · Blood · doi:10.1182/blood.2023023529 · Cited by 26
Landgren, O., Chari, A., Cohen, Y. C., Spencer, A. G., Voorhees, P. M., Sandhu, I., Jenner, M. W., Smith, D., Cavo, M., van de Donk, N. W. C. J., et al. (2024) · Blood · doi:10.1182/blood.2024025897 · Cited by 22
Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma
Ise, M., Matsubayashi, K., Tsujimura, H., & Kumagai, K. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.037 · Cited by 22
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Zamagni, E., Tacchetti, P., Pantani, L., & Cavo, M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1456331 · Cited by 22
TEMPI Syndrome: Erythrocytosis in Plasma Cell Dyscrasia
Zhang, X., & Fang, M. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.284 · Cited by 22
Frerichs, K. A., Bosman, P. W. C., Nijhof, I. S., Zweegman, S., & van de Donk, N. W. C. J. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.10.002 · Cited by 22
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
Feinberg, D. M., Paul, B. A., & Kang, Y. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103964 · Cited by 23
Melflufen for relapsed and refractory multiple myeloma
Oriol, A., Larocca, A., Leleu, X. P., Hájek, R., Hassoun, H., Rodríguez‐Otero, P., Paner, A., Schjesvold, F. H., Gullbo, J., & Richardson, P. G. G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1808884 · Cited by 24
Self-citationInsights into Modern Therapeutic Approaches in Pediatric Acute Leukemias
Panuciak, K., Margas, M., Makowska, K., & Lejman, M. (2022) · Cells · doi:10.3390/cells11010139 · Cited by 22
Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody
Micalizzi, D. S., Che, D., Nicholson, B. T., Jon, F., Desai, N., Lang, E. R., Toner, M., Maheswaran, S., Ting, D. T., & Haber, D. A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209563119 · Cited by 23
Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy
Landon‐Cardinal, O., Allard‐Chamard, H., Chapdelaine, H., Doucet, S., Rich, E., & Bourré‐Tessier, J. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223541 · Cited by 22
Raje, N. S., Faber, E. A., Richardson, P. G. G., Schiller, G. J., Hohl, R. J., Cohen, A. D., Forero, A., Carpenter, S. P., Nguyen, T. S., Conti, I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0201 · Cited by 24
Self-citationTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
Boudreault, J., Touzeau, C., & Moreau, P. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1285694 · Cited by 22
The challenges of checkpoint inhibition in the treatment of multiple myeloma
Paul, B. A., Kang, S., Zheng, Z., & Kang, Y. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.10.003 · Cited by 22
Castella, B., Melaccio, A., Foglietta, M., Riganti, C., & Massaia, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00508 · Cited by 24
Werle, E., Ziebart, J., Wasmund, E., & Eske-Pogodda, K. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000495773 · Cited by 22
Byun, J. M., Yoon, S., Koh, Y., Kim, I., Jo, J., Park, H., Lee, J., & Lee, J. (2019) · Anticancer Research · doi:10.21873/anticanres.13712 · Cited by 26
Recent Advances in the Management of Acute Lymphoblastic Leukaemia
Hodby, K. A., & Marks, D. I. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0712-8 · Cited by 22
Rosenberg, A. S., Bainbridge, S., Pahwa, R., & Jialal, I. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.07.016 · Cited by 21
Advances in CAR T Therapy for Hematologic Malignancies
Freyer, C. W., & Porter, D. L. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2414 · Cited by 21
Castillo, J. J., Libby, E. N., Ansell, S. M., Palomba, M. L., Meid, K., Flynn, C. A., Leventoff, C., Hergott, C. B., Sewastianik, T., Morgan, E. A., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020003087 · Cited by 21
Murphy, P. J., Glynn, D., Dias, S., Hodgson, R. M., Claxton, L., Beresford, L., Cooper, K. L., Tappenden, P., Ennis, K., Grosso, A., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25760 · Cited by 22
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M.-H., Posner, G., Ralston, S., Zagadailov, E. A., Ba-Mancini, A., & Rifkin, R. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.01.009 · Cited by 20
Musto, P., & Rocca, F. L. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1740084 · Cited by 22
Frerichs, K. A., Verkleij, C. P. M., Dimopoulos, M. A., Soto, J. A. M., Zweegman, S., Young, M. H., Newhall, K. J., Mutis, T., & van de Donk, N. W. C. J. (2021) · Cancers · doi:10.3390/cancers13102452 · Cited by 21
Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies
Ammannagari, N., Celotto, K., Neppalli, V. T., Lee, K. P., & Holstein, S. A. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.06.008 · Cited by 21
The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Shallis, R. M., Terry, C. M., & Lim, S. H. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1990-2 · Cited by 20
Kitada, M., Araki, S., & Koya, D. (2023) · Cells · doi:10.3390/cells12040595 · Cited by 21
Sharma, A., Gupta, K., Mishra, A., Lofland, G., Marsh, I. R., Kumar, D., Ghiaur, G., Imus, P. H., Rowe, S. P., Hobbs, R. F., et al. (2024) · Advanced Science · doi:10.1002/advs.202308617 · Cited by 18
New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing
de Vooght, K. M. K., Oostendorp, M., & van Solinge, W. W. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000276 · Cited by 20
Jiang, X. Y., Luider, J. M., & Shameli, A. (2019) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21837 · Cited by 20
Madduri, D., Dhodapkar, M. V., Lonial, S., Jagannath, S., & Cho, H. J. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.08.002 · Cited by 20
Cohen, C., Joly, F., Sibille, A., Javaugue, V., Desport, É., Goujon, J., Touchard, G., Fermand, J., Sirac, C., & Bridoux, F. (2021) · Diagnostics · doi:10.3390/diagnostics11030420 · Cited by 20
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3
Li, N., Spetz, M. R., Li, D., & Ho, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107892 · Cited by 20
CD38-Directed Therapies for Management of Multiple Myeloma
Hashmi, H., Husnain, M., Khan, A. Y., & Usmani, S. Z. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s259122 · Cited by 20
Wang, H., Xiao, X., Li, Z., Luo, S., Hu, L., Yi, H. J., Xiang, R., Zhu, Y., Wang, Y., Zhu, L., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215647 · Cited by 20
Role of daratumumab in the frontline management of multiple myeloma: a narrative review
Yadav, S., Gundeti, S., Bhave, A. A., Deb, U., Dixit, J., & Mishra, K. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2246651 · Cited by 20
Chung, I., Huang, W., Huang, Y.-T., Chen, M.-L., Tsai, A.-W., Wu, P.-Y., & Yuan, T.-T. T. (2023) · Oncology Reports · doi:10.3892/or.2023.8642 · Cited by 20
Mey, U., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T. N., Jehner, P., Rauh, J., Taverna, C., Schmid, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14481 · Cited by 22
The pharmacologic management of multiple myeloma in older adults
Dempsey, J. L., Johns, A. C., Rosko, A. E., & Lazarus, H. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1577822 · Cited by 20
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
Hosen, N. (2019) · Cancers · doi:10.3390/cancers11122024 · Cited by 23
Stocker, N., Gaugler, B., Ricard, L., de Vassoigne, F., Marjanovic, Z., Mohty, M., & Malard, F. (2020) · Cancer Medicine · doi:10.1002/cam4.2827 · Cited by 20
Evolving Role of Daratumumab: From Backbencher to Frontline Agent
Jain, A., & Ramasamy, K. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.010 · Cited by 20
Targeted Therapies for Multiple Myeloma
Leow, C. C.-Y., & Low, M. S. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050334 · Cited by 21
Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells
Fatehchand, K., McMichael, E. L., Reader, B. F., Fang, H., Santhanam, R., Gautam, S., Elavazhagan, S., Mehta, P., Buteyn, N. J., Merchand‐Reyes, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753145 · Cited by 19
ZDHHC9-mediated CD38 palmitoylation stabilizes CD38 expression and promotes pancreatic cancer growth
Guo, H., Lin, Z., Zhang, D., Qin, Q., Li, Z., Yin, Y., Chen, J., & Guo, W. M. (2025) · Communications Biology · doi:10.1038/s42003-025-07897-0 · Cited by 19
T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins
Xu, Y., Salazar, G. T., Zhang, N., & An, Z. (2019) · Antibody Therapeutics · doi:10.1093/abt/tbz001 · Cited by 19
Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab
Ye, Z., Wolf, L. A., Mettman, D. J., & Plapp, F. V. (2019) · Vox Sanguinis · doi:10.1111/vox.12864 · Cited by 19
Kiesewetter, B., Cherny, N. I., Boissel, N., Cerisoli, F., Dafni, U. G., de Vries, E. G. E., Ghia, P., Gökbuget, N., González‐Calle, V., Huntly, B. J. P., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000611 · Cited by 19
Girmenia, C., Cavo, M., Corso, A., Raimondo, F. D., Musto, P., Offidani, M., Petrucci, M. T., Rosato, A., & Barosi, G. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103623 · Cited by 19
Metadata
- Authors
- Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N. W. C. J., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N., & Richardson, P. G.
- Affiliations
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Harvard University (US)
- Karolinska University Hospital (SE)
- Lund University (SE)
- University Medical Center Utrecht (NL)
- University of Turin (IT)
- Janssen Research & Development (United States) (US)
- Genmab (Denmark) (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-24
- Volume
- 373
- Issue
- 13
- Pages
- 1207-1219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1902692042
- Semantic Scholar
- c731f1036338cb22a95a42420cb4ccf650d6c359
- Cited by
- 1,117
- References
- 27
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 63 · 2023: 87 · 2022: 83 · 2021: 134 · 2020: 131 · 2019: 108 · 2018: 129 · 2017: 125 · 2016: 143 · 2015: 14
- FWCI
- 107.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, daratumumab, CD38, monoclonal antibodies, relapsed/refractory multiple myeloma, monotherapy, dose escalation, progression-free survival, overall response rate, infusion reactions, pharmacokinetics, autologous stem cell transplantation, lenalidomide-refractory disease, bortezomib-refractory disease, pneumonia, thrombocytopenia, complete response, very good partial response
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, Pneumonia, Thrombocytopenia, Disease-Free Survival, Drug Resistance, Neoplasm, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
